September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Incindences of Endophthalmitis in Various Anti-VEGF Treatments
Author Affiliations & Notes
  • Mahdi Rostamizadeh
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • musa abdelaziz
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Achal Patel
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Majid Moarefi
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • David Miller
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Lawrence J Singerman
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Joseph Coney
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Michael Novak
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Llewelyn Rao
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Scott Pendergast
    Ophthalmology, Case Western, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Mahdi Rostamizadeh, None; musa abdelaziz, None; Achal Patel, None; Majid Moarefi, None; David Miller, None; Lawrence Singerman, None; Joseph Coney, None; Michael Novak, None; Llewelyn Rao, None; Scott Pendergast, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5025. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mahdi Rostamizadeh, musa abdelaziz, Achal Patel, Majid Moarefi, David Miller, Lawrence J Singerman, Joseph Coney, Michael Novak, Llewelyn Rao, Scott Pendergast; Incindences of Endophthalmitis in Various Anti-VEGF Treatments. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5025.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: Anti-vegf therapy has become the mainstay treatment of many retinal diseases. Though the risk of complications is relatively low, endophthalmitis remains the most devastating complication. The purpose of our study is to determine which anti vegf therapy – ranibizumab, bevacazimub, or afiblercept – had the most post injection endophthalmitis outcomes. We hypothesize that bevacazimub will have the highest rate, as it needs to be processed at a compounding pharmacy which has a higher potential of contamination.

Methods : Methods: After approval was obtained from Retina Associates of Cleveland institutional review board, electronic medical charts were searched based on international classification of disease codes 9 and 10 for intravitreal injections and endophthalmitis. A total of 110,246 injections were given over a 5 year period: 54,814 bevacizumab, 33,844 ranibizumab and 21,588 aflibervept. After accounting for duplicates, excluding cataract and bleb related endophthalmitis we identified 32 patients that had endophthalmitis after an injection. We divided the number of endophthalmitis cases by the total amount of injections in each group to find the incidence.

Results : Results: Out of all the patients given injections, 0.029% developed endophthalmitis. Bevacizumab was found to have the lowest at 0.016%. Ranibizumab had the second lowest at 0.029%. Aflibercept had the highest incidence of post injection endophthalmitis at 0.046%.

Conclusions : Conclusion: Our results show that aflibercept had the highest risk of post infectious endophthalmitis. Contrary to what we initially believed, bevacizumab had the least incidence of post infectious endophthalmitis. Research regarding patient preparation prior to therapy administration may reveal further differences between therapy results.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×